Tuesday, June 22, 2021

TOPICS

Home Tags Rubius Therapeutics

Tag: Rubius Therapeutics

Rubius Therapeutics posts $42.3M loss in Q1

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a $42.3 million loss in the first quarter of 2021, or 51 cents per diluted share, the...
RUBIUS THERAPEUTICS ended 2020 with a loss of $167.7 million.

Rubius Therapeutics reports $167.7M loss in 2020

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported Tuesday a loss of $167.7 million in 2020, or $2.08 per diluted share. The clinical-stage biopharmaceutical company, which...

Rubius Therapeutics reports $40.9M loss in Q3

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. reported a loss of $40.9 million, or 51 cents per diluted share, in the third quarter. The clinical-stage biopharmaceutical...
BEST-DRESSED: Rubius Therapeutics employees participate in a “Best Sweater” contest it held on behalf of the activities team in late 2019. It was accompanied by a “Giving Tree” for local families in need. / COURTESY RUBIUS THERAPEUTICS

Rubius Therapeutics

PBN Best Places to Work 2020 MIDSIZE COMPANIES 5. Rubius Therapeutics Employees in R.I.: 64 CEO Pablo J. Cagnoni Questions answered by: Human Resources Site Head Brianne Meehan What...
PROVIDENCE BUSINESS NEWS has announced that 66 companies will be recognized in its 2020 Best Places to Work program.

PBN announces 2020 Best Places to Work honorees

PROVIDENCE – Providence Business News has announced 66 honorees for its 2020 Best Places to Work program. Each of the companies recognized for this year’s...
RUBIUS THERAPEUTICS reported a loss of $48.5 million in the first quarter of 2020.

Rubius Therapeutics posts $48.5M loss in Q1; prioritizes on oncology and...

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. posted a loss of $48.5 million for the first quarter of 2020, or a loss of 60 cents...
RUBIUS THERAPEUTICS spent $163.5 million in 2019. The company does not yet generate revenue.

Rubius Therapeutics reports $163.5M loss in 2019; focuses on oncology and...

PROVIDENCE – Rubius Therapeutics Inc. reported a year-end loss of $163.5 million in 2019, an increase from $89.2 million in 2018. Loss per diluted share...
RUBIUS THERAPEUTICS reported a loss of $47 million in the third quarter.

Rubius Therapeutics posts $47M loss in Q3 on increase in R&D...

CAMBRIDGE, Mass. - Rubius Therapeutics Inc. reported a loss of $47 million in the third quarter, or 59 cents per diluted share, the company...
RUBIUS THERAPEUTICS reported a loss of $39.4 million in the second quarter of 2019. The company has yet to record revenue..4 million in the second quarter of 2019, The company is yet to have revenue.

Rubius reports $39.4M loss in Q2, heralds progress

PROVIDENCE – Rubius Therapeutics Inc. reported on Tuesday a loss of $39.4 million in the second quarter of 2019, or 50 cents per diluted...
BROADENED MISSION: Carol Malysz, executive director of Providence-based biotechnology trade association RI BIO, said the group has broadened its focus. Previously known as MedMates, this year the company changed its name and approach to promote the entire biotech industry.
 / PBN PHOTO/MICHAEL SALERNO

Ocean State starting to see growth in biotech industry

RI BIO, a Providence-based biotechnology trade association, is on a mission to put Rhode Island on the biotech industry’s map. Despite the state having...

Stay up to date with PBN's Morning Call & Daily Edition newsletters.

- Featured Event -

Latest News

Subscribe for 20% off today!

Sign-up to get the

PBN Daily Edition

A collection of all the published news of the last 24 hours, as well as selected features from PBN’s weekly print edition.

By submitting the form you agree to PBN's Privacy Policy and Terms of Use.

Subscribe with Providence Business News to keep reading.

We’re glad you are enjoying PBN.